ReviewMediterranean journal of hematology and infectious diseases2026
Efficacy and Safety of Thalidomidein Patients with Transfusion-Dependent B-Thalassemia: A Systematic Review, Meta-Analysis and GRADE Evaluation.
Review in Mediterranean journal of hematology and infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immunomodulatory drug thalidomide is a promising alternative therapy for transfusion-dependent β-thalassemia (TDT) due to its potent induction of fetal hemoglobin. Objective: To identify the efficacy and safety of thalidomide in TDT patients. Methods: A comprehensive search was conducted across MEDLINE, EMBASE, CENTRAL, Web of Science, CBM, CNKI, VIP, Wangfang Data, and OpenGrey, up to January 24, 2026. We included RCTs and observational studies involving more than 10 TDT patients treated with thalidomide for at least 3 months. Risk of bias was assessed using RoB 2 and MINORS tools. The certainty of evidence was evaluated with the GRADE approach. Results: Twenty-six studies involving 2422 patients were included. No studies had a high risk of bias. The meta-analysis of RCTs demonstrated that, compared with the control group, thalidomide significantly increased the major response rate (MRR; low certainty), the overall response rate (ORR; low certainty), and hemoglobin level (Hb; moderate certainty), as well as fetal hemoglobin level (HbF; moderate certainty). There was no significant between-group difference in changes in serum ferritin (SF) levels (very low certainty). The pre-post meta-analysis showed the following pooled outcomes: MRR 62.91% (very low certainty), ORR 75.07% (very low certainty), a Hb level change of 1.94 g/dL, a HbF level change of 39.21%, and an SF level change of -1432.39 ng/mL. The pooled incidence of adverse drug events (ADEs) was 4.65 per 100 person months, and that of ADEs leading to drug discontinuation was 0.04 per 100 person months. Most reported events were mild and tolerable. Conclusion: Thalidomide may provide limited benefits for TDT patients. In clinical practice, its potential risks must be thoroughly weighed against these benefits. Therefore, future large-scale, globally diverse, and high-quality RCTs are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.